Zai Lab (HKG:9688) incurred $101.8 million in net loss in the first half of the year, wider by 14% from $89.2 million a year earlier, according to a Wednesday filing to the Hong Kong stock exchange.
Loss per share came in at $0.09 compared with $0.08 a year earlier, the biopharmaceutical company said.
Net product revenue during the period fell 6% to $201.3 million from $214.7 million a year prior.